Calendar

November 2017
SunMonTueWedThuFriSat
 << <Oct 2017> >>
    123
45678910
11121314151617
18192021222324
252627282930 

Announce

Who's Online?

Member: 0
Visitor: 1

rss Syndication

Posts sent on: 2001-01-01

Oct092014

The Bristol Press: Bristol, Conn., And Surrounding Areas (bristolpress.com)









30, but Perris presence will be waived if shes compliant with her treatment. On that date, the court will get a report on her progress. Perri, who was arrested on Aug. 11 on two warrants each charging her with a single count of sale of narcotics, rejected another deal offered by the state that would have sent her to prison for two years with no probation. Her attorney, Alfonzo Sirica, said she was somewhat reluctant to enter the program given the lengthy prison term that hangs over her head if she doesnt succesfully complete treatment. If she leaves the treatment program, doesnt comply with its terms or is charged again by police, she could be sentenced to the seven-year cap to which she agreed. I firmly believe that people who sell crack cocaine should go to jail, not for months, but for years, said Ronald Dearstyne, the prosecutor. But, well give her this chance. Dearstyne also said the lengthy prison term on the table if Perri is non-compliant is partially based on her drug dealing history. She was convicted in April 2012 of sale of hallucinogen/narcotic and sentenced to a year in prison. Perri, when she was arrested on Aug. 11 in her apartment on her most recent cases, admitted to police that she had two paper folds of heroin in her bra and four more in her wallet, according to the police report.




To read more from the author please visit http://www.bris.ac.uk/

Admin · 29 views · Leave a comment
Oct082014

The hot tickets



Lenny Henry

Homeward bound … Lenny Henry. Photograph: Sarah Lee for the Guardian

Book now

■ Rudy's Rare Records

Following his triumphs in Northern Broadsides' Othello, Lenny Henry is back on home turf in this stage version of the warm-hearted Radio 4 series set in an old reggae record shop in Brum. Larrington Walker co-stars, and a live on-stage band will soundtrack the show with covers of Cliff, Dekker and Marley. The Rep, Birmingham (0121-236 4455), 4-20 September; Hackney Empire, London (020 8985 2424), 24 September-5 October.

■ The Promise

The Arnolfini has always had bold ambitions for Bristol, and its summer exhibition writs them large across the city, with both a gallery show and off-site commissions that reimagine Bristol's future – and past. Look out for Gabriel Lester's Aeolian harps on the harbourside, and book into an August boat ride to see the full works. Arnolfini, Bristol (0117-917 2300), until 9 November.

■ Titus Andronicus

Is multi-storey the new immersive? After Macbeth in a Poplar tower block, here's Titus Andronicus in a Peckham car park, with a beatboxed score by BellaTrix, a local community chorus and added parkour, as cast members take a running leap and a jump at Shakespeare's bloodiest play. Bold Tendencies, Peckham Rye Multistorey Carpark, London, 30 August- 30 September.

Book now

■ Hotel

A British family are holidaying on a remote Kenyan island. Mother is a senior politician, father has been involved in an internet scandal, and son has his own secrets to hide. Polly Stenham's latest has echoes of John Osborne and Sarah Kane amid its middle-class setting. Get day tickets for this Shed show to see for yourself. National Theatre, London (020-7452 3000), until 2 August.


Admin · 1025 views · Leave a comment
Oct032014

Bristol-myers To Transfer $1.4 Bln In U.s. Pension Obligations To Prudential - Nasdaq.com









retirees and their beneficiaries who started receiving their monthly retirement benefit payments on or before June 1, 2014. Bristol-Myers Squibb said its U.S. Retirement Plan ("the Plan") is in a strong financial position, and the obligations associated with this transaction will require no additional cash contributions by the company. There will be no change to the monthly retirement benefit payments currently received by retirees and their beneficiaries. All other plan participants will stay in the company's Plan, which is well-funded.




To read more from the author please visit http://en.wikipedia.org/wiki/Bristol

Admin · 22 views · Leave a comment
Oct012014

Bristol-myers To Transfer $1.4 Bln In U.s. Pension Obligations To Prudential - Nasdaq.com









retirees and their beneficiaries who started receiving their monthly retirement benefit payments on or before June 1, 2014. Bristol-Myers Squibb said its U.S. Retirement Plan ("the Plan") is in a strong financial position, and the obligations associated with this transaction will require no additional cash contributions by the company. There will be no change to the monthly retirement benefit payments currently received by retirees and their beneficiaries. All other plan participants will stay in the company's Plan, which is well-funded.




To read more from the author please visit http://en.wikipedia.org/wiki/Bristol

Admin · 21 views · Leave a comment
Oct012014

Bristol Immune Drug Shows Strong Effect In Melanoma Study - Yahoo Finance









The data has been keenly awaited since this is the first presentation of results from a pivotal Phase III clinical trial of a promising new class of drugs designed to help the body's own immune system fight cancer. In the study, involving people with advanced melanoma, 32 percent of patients saw their tumours shrink when given Opdivo against 11 percent of those treated with conventional chemotherapy drugs. Importantly, the duration of response was also much longer. Patients on chemotherapy typically responded for 3.6 months, whereas 95 percent of those who responded to Opdivo were still benefiting after six months and the median duration of response was not reached. "I was very nicely surprised," said Jeffrey Weber of the Moffitt Cancer Center in Florida, who presented the results at the European Society of Medical Oncology annual congress on Monday. "A 32 percent response rate with the majority staying in remission past six months is probably going to turn into a very impressive level of survival," he added. Opdivo, or nivolumab, is part of a promising new class of drugs designed to block a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumours to evade the immune system's disease-fighting cells. The drug became the first PD-1 inhibitor to receive regulatory approval anywhere in the world in July when Japanese regulators gave it a green light, although it has been beaten to market in the United States by Merck & Co's rival Keytruda, which was approved earlier this month. On Friday, Bristol-Myers said the U.S.




To read more from the author please visit http://www.bristol-hotel-bookings.co.uk/page3.html

Admin · 20 views · Leave a comment

Previous page   ... 9 ... 15, 16, , 17 ... 23 ... 31  Next page